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Abstract Based on the template of a recently introduced
derivatization reagent for aldehydes, 4-(2-(trimethylammo-
nio)ethoxy)benzeneaminium dibromide (4-APC), a new
derivatization agent was designed with additional features
for the analysis and screening of biomarkers of lipid
peroxidation. The new derivatization reagent, 4-(2-((4-
bromophenethyl)dimethylammonio)ethoxy)benzenaminium
dibromide (4-APEBA) contains a bromophenethyl group to
incorporate an isotopic signature to the derivatives and to
add additional fragmentation identifiers, collectively en-
hancing the abilities for detection and screening of
unknown aldehydes. Derivatization can be achieved under
mild conditions (pH 5.7, 10 °C). By changing the
secondary reagent (1-ethyl-3-(3-dimethylaminopropyl) car-
bodiimide instead of sodium cyanoborohydride), 4-APEBA
is also applicable to the selective derivatization of carbox-
ylic acids. Synthesis of the new label, exploration of the
derivatization conditions, characterization of the fragmen-
tation of the aldehyde and carboxylic acid derivatives in
MS/MS, and preliminary applications of the labeling
strategy for the analysis of aldehydes in urine and plasma
are described.
Keywords Derivatization.Aldehydes.Carboxylic
acids.4-APEBA.4-APC.LC–MS/MS.Lipid peroxidation
Introduction
One of the incentives in the initial development of
combined liquid chromatography–mass spectrometry (LC–
MS) was to avoid the need for analyte derivatization [1],
which is often needed in gas chromatography (GC) and
may be considered as one of the limitations of GC–MS. In
GC, derivatization of more polar compounds is obligatory
to enable the GC analysis, whereas in GC–MS it may also
improve ionization and/or fragmentation characteristics.
However, because analyte ionization in LC–MS heavily
relies on liquid-phase or gas-phase acid–base chemistry,
analyte derivatization must be advantageous for analytes
with poor properties in that respect. Early accounts on the
derivatization of, for instance, prostaglandins [2]a n d
steroids [3] for LC–MS show this. At present, analyte
derivatization in LC–MS is frequently used in the analysis
of compound classes like steroids [4, 5], sugars [6], and
amino acids [7]. In the latter case, the derivatization is not
only directed at improving the detectability but also at
enhancing the chromatographic properties. In general,
analyte derivatization may be performed for various
reasons: increase the stability of the analyte, improve the
separation from matrix components in sample pretreatment
and/or chromatography, enhance the ionization efficiency,
and/or alter the fragmentation characteristics in MS.
Two compound classes for which derivatization for LC–
MS is highly desirable or even obligatory are aldehydes and
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considered important biomarkers of oxidative stress and
free radical damage. Lipid peroxidation (LPO), one of the
main consequences of free radical damage, is implied in
various diseases. Aldehydes and carboxylic acids may be
formed as a result of LPO and, as such, both classes have
been extensively studied as potential biomarkers of reactive
oxidative species and/or radical damage [8–10]. Next to
GC–MS [11] and various other methods [12, 13], LC–MS
has become an important tool in the analysis of both
aldehydes [14–17] and carboxylic acids [18, 19]. However,
some problems are associated with this. Aldehydes can be
measured directly in plasma but, when extracted from
urine, they may suffer from degradation to aliphatic
carboxylic acids [20]. Moreover, the volatility and intrinsi-
cally low response of aldehydes in LC–MS present
analytical challenges. Carboxylic acids, on the other hand,
are more stable but cannot be easily analyzed in positive-
ion mode. In all these analytically challenging cases, the
concept of derivatization can play an accelerating role.
From an organic–chemical perspective, derivatization
involves an organic reaction of an analyte molecule with
a suitable derivatization reagent. Thus, derivatization
reagents contain a reactive functional group that (selec-
tively) reacts with a complementary functional group in
the analyte. For LC–MS, the derivatization strategy is
typically directed at the incorporation of a group with a
charge (cationic groups for positive-ion mode and strongly
acidic functionality for negative-ion mode) or other groups
that enhance ionization (secondary or tertiary amine for
positive-ion mode or aromatic nitro groups in negative-ion
mode). This combination of a chemical and analytical
component can be found in a variety of agents that are
available for aldehyde derivatization, such as the commer-
cially available hydrazine-based Girard T and P reagents and
dinitrophenylhydrazine [15, 21–23].
However, many of these off-the-shelf reagents still possess
drawbacks,suchaslackofselectivityorformationofunstable
derivatives. More advanced derivatization agents, in which
the chemical structure of the reagent has been fine-tuned to
address such issues, have been reported [4, 17, 22–26], but
mostly on a scattered basis. Recently, we reported [27, 28]a
novel derivatization agent, 4-(2-(trimethylammonio)ethoxy)
benzeneaminium dibromide (4-APC; Fig. 1a). 4-APC was
designed for the selective determination of aldehydes in
biological samples by positive-ion electrospray ionization–
mass spectrometry (ESI–MS). Inspired by the interesting
chemical and analytical properties of 4-APC, we decided to
use it as a design template to address some additional
stringent features of (oxidative) biomarker analysis. First,
incorporation of an element with multiple stable isotopes
would give a significant advantage as it allows the specific
screening for unknown derivatives easily visible by their
incorporated isotopic signature. Second, the signal-to-noise
ratio should be as high as possible. Third, the fragmentation
patterns of the adducts in tandem MS (MS/MS) should give
several different types of information, thus enabling powerful
MS acquisition strategies such as not only selected reaction
monitoring (SRM) but also neutral loss and/or precursor-ion
analysis modes. Fourth, an ideal scenario would involve the
use of one derivatization agent for multiple analyte classes
with reactivity being directed by a co-reagent.
Fig. 1 Structures of derivatization reagents and relevant reaction
pathways. a Reaction of 4-APC and hexanal (blue) through a transient
imine. b Reaction of 4-APEBA and hexanal (blue) through a transient
imine. c Reaction of 4-APEBA with hexanoic acid (green) through a
transient O-acyl-isourea. In reaction C, the R and R1 groups arbitrarily
represent the two peripheral groups of EDC
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and analytical properties of a novel derivatization reagent 4-
(2-((4-bromophenethyl)dimethylammonio)ethoxy)benzena-
minium dibromide (4-APEBA; 1 in Figure 1b)t h a t
addresses these four demands. Compared to the first-
generation reagent 4-APC, 4-APEBA contains an extra
bromophenethyl group which results in several benefits.
The isotopic signature of
79Br and its
81Br isotope (100:98)
provides confirmation of the presence of bromine in the
derivatives. Furthermore, the total molecular mass of 4-
APEBA derivatives is higher than that of 4-APC deriva-
tives resulting in a higher signal-to-noise ratio in biological
samples. The fragmentation of 4-APEBA derivatives dis-
plays an additional advantage in the form of consistent
fragments and neutral losses. Last, it will be shown how a
simple switch of co-reagent (EDC instead of NaBH3CN)
turns 4-APEBA into a selective derivatization reagent for
aliphatic carboxylic acids. Preliminary studies on aldehyde
analysis in urine and plasma demonstrate its applicability in
biological samples.
Experimental
Chemicals Pentanal, hexanal, heptanal, octanal, nonanal,
decanal, pentanoic acid, hexanoic acid, heptanoic acid,
octanoic acid, nonanoic acid, sodium cyanoborohydride
(NaBH3CN), ammonium acetate, 2,2′-azobis(2-amidopro-
pane) dihydrochloride (AAPH), dichloromethane (DCM),
NaOH, Na2SO4, KOH, ethyl acetate (EtOAc), methyl-tert-
butyl ether (MTBE), aq. HBr solution, ethanol (EtOH), 2-
(4-bromophenyl)ethanamine, formaline, formic acid (for
synthesis), and human plasma were all purchased from
Sigma-Aldrich (Zwijndrecht, The Netherlands). Methanol
(MeOH), acetonitrile (MeCN), and formic acid (for
analysis) were purchased from Biosolve (Valkenswaard,
The Netherlands). 1-Ethyl-3-(3-dimethylaminopropyl) carbo-
diimide (EDC) and N-hydroxysuccinimide (NHS) were
purchased from Perbio Science (Etten-leur, The Netherlands).
4-APC dibromide was prepared according to the procedure
reported before [28]. The urine was obtained from five
human volunteers.
2-(4-Bromophenyl)-N,N-dimethylethanamine (3) A solution
of 2-(4-bromophenyl)ethanamine 2 (4.0 g, 20.1 mmol) in
formaline (30% aq, 60 ml) and formic acid (50 ml) was
heated to reflux for 5 h. The solution was concentrated by
rotary evaporation. The solid residue was stirred with
NaOH solution (10%, 50 ml) for 0.5 h. DCM was added;
the whole was stirred vigorously for 5 min, and the layers
were separated. The aqueous layer was extracted twice
more with DCM. The combined organic layers were dried
(Na2SO4) and concentrated. Some solid condense was
observed in the rotary evaporator. The residue was mixed
with water (50 ml) and sonicated for 5 min. DCM (50 ml)
and solid KOH (approximately 10 g) were added; the whole
was stirred vigorously for 5 min, and the layers were
separated. The organic layer was dried (Na2SO4), concen-
trated, and dried. The title compound was obtained as a
yellow oil (3.8 g, 16.7 mmol, 83%). This compound was
pure enough for further manipulation. The synthesis of this
compound by a different route has been disclosed, but no
nuclear magnetic resonance (NMR) data have been reported
[29].
1H-NMR data are presented in the Electronic
Supplementary Material.
N-(4-(2-Bromoethoxy)phenyl)acetamide (4) Prepared
according to Eggink et al. [28].
2-(4-Acetamidophenoxy)-N-(4-bromophenethyl)-N,N- dime-
thylethanaminium bromide (5) Amine 3 (3.4 g, 14.9 mmol)
and bromide 4 (3.8 g, 14.7 mmol) were mixed with MeCN
(18 ml). The suspension was briefly warmed (approximately
10 s), resulting in a dark-brown clear solution. The solution
was stirred in the dark for 4 days at room temperature. During
this time, the product gradually precipitates. EtOAc (20 ml)
was added dropwise to the suspension. The solid is filtered,
washed with EtOAc (2×), and dried. The title compound is
obtained as an off-white solid (5.15 g, 72%) with sufficient
purity for further synthetic manipulations. An analytical
sample can be obtained by recrystallization from a mixture
of MeOH, MeCN, and MTBE to give beige crystals. M.p.=
194.4–195.2 °C. NMR data are presented in the Electronic
Supplementary Material.
4-(2-((4-Bromophenethyl)dimethylammonio)ethoxy)
benzenaminium dibromide (1, 4-APEBA)
Salt 5 (2.5 g, 5.17 mmol) was mixed with water (28 ml),
giving a suspension. Then, aq. HBr solution (48%, 46 ml)
was added, resulting in a clear solution. The mixture was
heated to reflux for 45 min. The solvent was removed by
rotary evaporation, and the residue was dried at 80 °C for 2 h.
The solid residue was scraped off the walls of the flask and
transferred to another flask. The solid was recrystallized from
warm (not hot) EtOH/water. This afforded brown crystals
(1.4 g, m.p.=229.8–230.6 °C) which were shown to contain
both 20% EtOH solvate and ∼2% of an impurity. The
following second recrystallization effectively removed both
these impurities. A total of 1.2 g of the material was mixed
with H2O (2.0 ml). The suspension was warmed to ∼60 °C,
and more H2O was added until complete dissolution (final
volume ∼5m lH 2O). The mixture was left overnight in the
dark at room temperature. The crystals were filtered, washed
with ice-cold water (2.0 ml + 3.0 ml), and dried. This
afforded beige needles with >98% purity (660 mg, extrap-
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in the dark. Full chemical characterization and solution
stability of 4-APEBA are presented in the Electronic
Supplementary Material.
Sample pretreatment and derivatization
Aldehyde derivatization For 4-APC derivatization reactions,
200µlof2.5mg/ml4-APCdibromidein150mMammonium
acetate buffer pH 5.7, 50 µl 0.75 mg/ml NaBH3CN in
methanol, and 250 µl of the 500 nM aldehyde standards
pentanal, hexanal, heptanal, octanal, nonanal, and decanal (in
H2O) were taken. For the 4-APEBA derivatization reactions,
200 µl of 3 mg/ml 4-APEBA dibromide in 150 mM
ammonium acetate buffer pH 5.7, 50 µl of 0.5 mg/ml
NaBH3CN in methanol, and 250 µl of the aldehyde
standards pentanal, hexanal, heptanal, octanal, nonanal, and
decanal (in H2O) were taken. The derivatization reactions
were carried out at 10 °C in the thermostated Agilent 1200
autosampler. After 3 h, the first sample was injected in the
LC–MS/MS for analysis.
The urine/plasma samples were centrifuged at 13,600 rpm
for 15 min at 10 °C before performing the derivatization
reaction.Thederivatizationwascarriedoutinthesamewayas
the standard solutions. After 3 h, the first sample was injected
in the LC–MS/MS for analysis.
Carboxylic acid derivatization For the derivatization reac-
tions,200µlof3mg/ml4-APEBAdibromideinH2O, 50 µl of
100 mM NHS buffer pH 5.7, 50 µl of 290 mM EDC in H2O,
and 200 µl of carboxylic acid standards pentanoic acid,
hexanoic acid, heptanoic acid, octanoic acid, and nonanoic
acid (1 mM in H2O) were used. In this case, the derivatization
was carried out at 60 °C for 1 h in the thermostatic column
oven in closed vials before injection.
In vitro oxidation of human plasma and analysis of formed
aldehydes Two hundred microliters of human plasma was
mixed with 50 µl of AAPH solution (final concentration
1 mM), and the mixture was incubated at 37 °C for 4 h. An
amount of 50 µl was taken from the solution and mixed
with 50 µl of cold ACN, vortexed for 1 min, and
centrifuged for 20 min at 13,600 rpm at 4 °C. For the
derivatization, 50 µl of sample was mixed with 40 µl of
3 mg/ml 4-APEBA dibromide in 150 mM ammonium
acetate buffer pH 5.7 and 50 µl of 0.5 mg/ml NaBH3CN in
H2O. The control experiment was performed similarly with
the exception that 50 µl of H2O was added instead of
AAPH, without any incubation time.
HPLC All high-performance liquid chromatography
(HPLC) separations were performed on an Agilent 1200
HPLC system (Agilent Technologies, Amstelveen, The
Netherlands) controlled by the Agilent Masshunter soft-
ware. A Waters XTerra MS reversed-phase column (C18,
100×2.1 mm, 3 µm) at 45 °C and with a flow rate of
150 µl/min was used for the separation of the derivatized
aldehydes, carboxylic acid standards, and urine and plasma
samples. Samples were injected (10 µl) from a thermostatic
autosampler kept at 10 °C. The gradient elution was
programmed as follows: After injection, 100% mobile
phase A (95% H2O + 5% MeOH + 0.1% formic acid)
was maintained for 5 min and then solvent B (5% H2O+
95% MeOH + 0.1% formic acid) was increased from 5% to
90% in either 15 min (short gradient) or 25 min (long
gradient) with a 5-min hold at 90% B. After this, the
column was reconditioned for 10 min at 100% mobile
phase A. The effluent from the LC column was directed to
the mass spectrometer.
Mass spectrometry LC–MS or LC–MS/MS were performed
on anAgilent quadrupole time-of-flight (Q-TOF) hybridmass
spectrometer equipped with an Agilent 1200 LC system
(Agilent Technologies, Amstelveen, The Netherlands).
Positive-ion ESI–MS data were collected using capillary
voltage of 3.5 kV, a fragmentor voltage of 120 V, skimmer at
65V,andspectrumacquisitioninthem/z range of 100–1,000.
T h es o u r c eg a st e m p e r a t u r ew a ss e tt o3 5 0° Cw i t ha
drying gas flow of 7 l/min and a nebulization gas pressure
of 15 psig. The collision energy was optimized for the best
fragmentation patterns and was typically 60–80 V. Two
internal calibrants with m/z 622.0290 and 922.0098,
sprayed with a separate nebulizer, were employed to
improve mass accuracy.
Results and discussion
Design and synthesis
As explained, for identification and characterization of
known and unknown LPO biomarkers, we required a
derivative of 4-APC which was further tailored with respect
to four design demands. The incorporation of an element
with multiple stable isotopes was envisaged through
incorporation of a bromo group, which has two major
isotopes separated by two atomic mass units (79 and 81) in
a 100:98 ratio. Several sites of Br attachment were
considered. Given that steric requirements and the pKa of
the aniline moiety (vide infra) play crucial roles in the
actual derivatization reaction [27, 30], bromo substitution
on the 3- or 2-position of the oxy-aniline head was deemed
suboptimal because of potentially compromised steric
accessibility and/or a likely drop in the pKa (e.g., pKa≈4
for 3-bromo-4-methoxyaniline [31]). A better alternative
was to replace one of the N-methyl groups in 4-APC by a
668 M. Eggink et al.4-bromophenyl-containing group, also because this would
simultaneously address the second demand of increased
mass and associated increase in signal-to-noise ratio. To
maintain the highest chemical stability and optimal MS
sensitivity, a C2 spacer between the charged group and the
bromophenyl moiety, i.e., a bromophenethyl group, was
preferred over a C0 or C1 spacer. Moreover, it was hoped
that this phenethyl group would deliver an additional and
reliable fragmentation site, thus aiding in the third demand.
All these new chemical features were deliberately
installed remote from the aniline head. This ensures an
anilinium pKa very similar to that of 4-APC (∼5.3) [27],
which itself was deemed important for two reasons. First,
the reaction with aldehydes will remain highly predictable.
Second, the unique pKa also opens doors for the reaction of
the candidate aniline with other carboxyl groups, such as
carboxylic acid biomarkers. A typical derivatization cock-
tail for carboxylic acids will involve the use of EDC [32],
which provides a transient O-acyl-isourea which is trapped
by a nucleophile. In aqueous media of any relevant pH,
aliphatic amines (pKa ∼ 10–11) are substantially more
deactivated by protonation compared to anilines, which
possess a lower pKa. This very difference bodes well for
assistance in the fourth demand by enabling a relatively
straightforward reaction of the aniline candidate with
carboxylic acids in the presence of EDC.
Taken together, the design steps ultimately called for the
previously unknown 4-APEBA (1 in Fig. 1b)a st h et a r g e t
compound. The developed synthesis was similar to that of 4-
APC [28] with the difference that, instead of NMe3,2 - ( 4 -
bromophenyl)-N,N-dimethylethanamine (3) was required. The
synthesis consists of four steps only requiring recrystalliza-
tions as purifications (see Electronic Supplementary Material).
Using this readily scalable protocol, more than a gram of
crystalline, pure, and stable 4-APEBA was prepared.
Reactivity and analytical properties of 4-APEBA
Derivatization of aldehydes
First, we cross-checked 4-APEBA in the derivatization of
aldehydes against first-generation reagent 4-APC. For the
latter, we already showed that the derivatization of aliphatic
aldehydes took less than 30 min to complete [27]. As
shown in Fig. 2a, the derivatization of aldehydes with 4-
APEBA at 10 °C and pH 5.7 proceeds at the same speed as
with 4-APC. This reinforces our earlier notion that
maintaining the exact same aniline head would lead to
identical derivatization chemistry (Fig. 1a, b). The low
reaction temperature is important because of the volatility of
the aldehydes. Calibration curves, ranging from 0 to 200 nM
pentanal and heptanal derivatized with either 4-APC or
4-APEBA, show similar linearity, slope, and intercept
(see Electronic Supplementary Material Figure S10).
Despite the fact that for 4-APEBA-derivatized aldehydes
the ion intensity is split over the two Br isotope peaks, the
response for the 4-APC derivatives of pentanal and heptanal in
the extracted-ion chromatograms (with m/z 265 and 293,
respectively) is the same as that for the 4-APEBA derivatives
of pentanal and heptanal (with m/z 433 and 461, respectively).
This indicates that an about twofold increased response is
obtained with the 4-APEBA labeling compared to the 4-APC
labeling. Thus, 4-APEBA is at least an equally effective and
sensitive derivatization agent as 4-APC.
Derivatization of carboxylic acids
Next, we explored the reactivity of 4-APEBA with
carboxylic acids. Carboxylic acids are a special class of
carbonyl biomarkers because deprotonation under (sub)
neutral conditions leaves the carbonyl group unreactive as
Fig. 2 Reactionkinetics at 10°C of4-APEBAwith: a aldehydes (trans-
2-pentenal, pentanal, hexanal, heptanal, octanal, nonanal, decanal) in the
presence of NaBH3CN. b Aliphatic acids (pentanoic acid, hexanoic
acid, heptanoic acid, octanoic acid, and nonanoic acid) in the presence
of EDC and NHS
Targeted LC–MS derivatization for aldehydes and carboxylic acids with 4-APEBA 669an electrophile. However, as extensively demonstrated by
others before [33, 34], treatment of a carboxylic acid with
reagents like EDC transforms the carboxylic acid to a
transient O-acyl-isourea [32], which can be trapped by a
NH2 nucleophile through its now highly electrophilic
carbonyl. Figure 1c depicts this reaction sequence for 4-
APEBA in comparison to the reaction with aldehydes
(Fig. 1b). Collectively, the protocol involving EDC allows
attachment of the NH2 group to a carboxylic acid. Under
physiological conditions, this sequence is expected to be
especially applicable to amines with a somewhat lower pKa,
such as 4-APEBA (vide supra).
To test this hypothesis, we turned to a reported
procedure which uses a cocktail of EDC and NHS [35,
36]. The use of NHS has been reported to increase the
efficiency of EDC-mediated coupling reactions. Indeed,
preliminary experiments with a cocktail of 4-APC, NHS,
and EDC gave amide adducts with simple carboxylic acids
(data not shown). When extended to 4-APEBA, we found
that the short-chain aliphatic carboxylic acids are fully
reacted within 300 min at 10 °C (Fig. 2b). The derivatiza-
tion process can be accelerated by heating the reaction
mixture to ∼60 °C, which is compatible with carboxylic
acids because they are relatively nonvolatile. Figure S11,
Electronic Supplementary Material, shows the extracted-ion
chromatograms of 4-APEBA-derivatized pentanoic acid,
hexanoic acid, heptanoic acid, octanoic acid, and nonanoic
acid. The MS traces show the typical isotopic pattern for
one bromine.
The stability of the reaction products has not yet been
systematically investigated. In our current experience, no
changes in peak areas were observed when samples
standing in the autosampler were analyzed on three
consecutive days.
MS/MS fragmentation of 4-APEBA aldehyde derivatives
Because the 4-APEBA derivatives of aldehydes and carboxylic
acids contain a permanent positive charge, they can be
readily analyzed using positive-ion ESI–MS. The M
+ ion is
observed for all compounds without fragmentation. Using
collision-induced dissociation in MS/MS, two types of frag-
ments are observed, that is: compound-specific fragments that
still contain the (derivatized) aldehyde or carboxylic acid
group and reactant-specific fragments resulting from bond
cleavages with charge retention on the reactant side. The m/z
values of the compound-specific fragments depend on the
aldehyde or carboxylic acid analyzed, whereas the m/z values
of the reactant-specific fragments are the same, irrespective of
the compound analyzed.
In MS/MS, all tested 4-APEBA-derivatized aldehydes
showed similar fragmentation. As an example, the spectrum
of the nonanal derivative (C27H42BrN2O
+ with m/z 489.213)
i ss h o w ni nF i g .3a.T h eM
+ precursor ion shows
characteristic neutral losses of 227 and 255 amu,
corresponding to the loss of 4-bromophenethyl dimethyl-
amine (loss of C10H14BrN) and of both 4-bromophenethyl
dimethylamine and ethene (loss of C12H18BrN). The m/z
Fig. 3 TypicalMS/MSspectraof4-APEBA-derivatizedcarbonylcompoundsa 4-APEBA-derivatized nonanal, b 4-APEBA-derivatized octanoic acid
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aldehyde derivatized, that is m/z 262 and 234 for the 4-
APEBA-derivatized nonanal (cf. Fig. 3a). In terms of
cleavage site and fragmentation pattern, these losses corre-
spond to the losses of 59 and 87 amu in 4-APC-derivatized
aldehydes [28]. Proposed structures for these fragments,
involving a stable oxirane ring in the ion with m/z 262 and a
protonated quinone imine in the ion with m/z 234, are given
in the Electronic Supplementary Material (Figure S12A and
S12B). In addition, four characteristic fragments are ob-
served, the m/z values of which are independent of the
aldehyde derivatized. The fragment ion with m/z 183
(C8H8Br
+) corresponds to the 4-bromophenethyl cation (for
structure, see Electronic Supplementary Material
Figure S12C), whereas the other fragments are related to
the quaternary ammonium group, that is the immonium ions
with m/z 58 (C3H8N
+)a n dm/z 72 (C4H10N
+), and the
quaternary ammonium ion with m/z 104 (C5H14NO
+).
MS/MS fragmentation of 4-APEBA-derivatized carboxylic acid
The fragmentation of 4-APEBA-derivatized carboxylic
acids in MS/MS is dominated by the cleavage between
the 4-bromophenethyl group and the rest of the molecule,
resulting in two complementary fragments, that is, an
abundant fragment ion with m/z 183 due to the 4-
bromophenethyl cation (C8H8Br
+, see Electronic Supple-
mentary Material Figure S13B) and an [M–182]
+ ion,
which is found with m/z 307 for 4-APEBA-derivatized
octanoic acid (Fig. 3b).
Next to this structure-specific [M–182]
+ fragment ion,
another structure-specific fragment ion is observed due to
the loss of 227 amu, which corresponds to the loss of 4-
bromophenethyl dimethylamine (loss of C10H14BrN, also
observed with 4-APEBA-derivatized aldehydes (see Elec-
tronic Supplementary Material Figure S13A)). Fragments
related to the quaternary ammonium group are also
Fig. 4 LC–MS/MS traces of 4-APEBA derivatives of butanal,
pentanal, hexanal, heptanal, octanal, nonanal, and decanal: a Com-
bined XIC of compound-specific fragments, b extracted-ion chro-
matogram (EIC) of the fixed neutral loss of the mass 227 amu, c EIC
of the reactant-specific fragment ion with m/z of 183. For the
separation, the long gradient described in experimental was used
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with m/z 58,72, and 104).
Features of 4-APEBA derivatization in biomarker detection
and screening
After derivatization, both the aldehydes (pentanal, hexanal,
heptanal, octanal, nonanal, and decanal) and the carboxylic
acids (pentanoic acid, hexanoic acid, heptanoic acid,
octanoic acid, nonanoic acid) can be readily separated on
a reversed-phase C18 column using a methanol/water
gradient (containing 0.1% formic acid).
Based on the (fragmentation) characteristics of the 4-
APEBA derivates, one may envisage various strategies to
optimize detection of known aldehyde and carboxylic acid
biomarkers, to confirm their identity, and/or to screen for
unknown aldehyde or carboxylic acid biomarkers.
In single MS applications, the presence of the bromine in
the 4-APEBA label provides an isotopic signature to all
derivatized compounds of two isotope peaks of almost
equal abundance with an m/z difference of two.
In MS/MS applications, this isotopic signature can still
be retained if a wider than unit mass precursor-ion selection
window is applied, as is currently often practiced in ion trap
and Q-TOF instruments. In the current research, a Q-TOF
instrument was applied. In targeted analysis with a Q-TOF
instrument, MS1 may be set to select particular precursor
ions in prespecified time segments of the chromatogram
(time-scheduled product-ion MS/MS). Next to extracted-
ion chromatograms for known m/z values of compound-
specific fragments (Fig. 4a), the resulting data sets may be
interrogated to provide either neutral loss chromatograms
(fixed neutral loss of 227 amu for both aldehydes (Fig. 4b)
and carboxylic acids or 182 amu for carboxylic acids) or
extracted-ion chromatograms for the common (reactant-
specific) fragments with m/z 183 and 58 (Fig. 4c).
Although a Q-TOF instrument was used by us, targeted
analysis could also readily be performed using a triple–
quadrupole instrument, operated either in the SRM mode to
detect compound-specific transitions of M
+ to particular
fragments, in the neutral loss scan mode (fixed neutral loss
of 227 amu for aldehydes and carboxylic acids or 182 amu
Fig. 5 Combined extracted-ion chromatograms for five 4-APEBA-derivatized urine samples spiked with 20 nM of hexanal, heptanal, octanal,
nonanal, and decanal. Individual peaks are labeled with the peak area. For the separation, the short gradient described in experimental was used
672 M. Eggink et al.for carboxylic acids) or in the precursor-ion scan mode
(with fixed (reactant-specific) product ions with m/z 183
and/or 58). The use of a triple–quadrupole instrument was
not attempted in this project.
Biological applications
Analysis of aldehydes in urine
New mechanistic insights on LPO products continue to
emerge, often because biomarkers of novel structure are
found [20]. We believe that our reagents 4-APC [27, 28]
and especially 4-APEBA can be very useful in the detection
and screening of LPO biomarkers. Based on the use of
derivatization with 4-APC, we have previously described
the detection of elevated aldehyde concentrations in urine
[27] as well as the formation of oxidized aldehydes like 4-
HNE in plasma by the treatment with an radical inducer
[28]. The 4-APEBA derivatization agent is designed to
extend this work, as it shows important features for the
detection of unknown biomarkers by LC–MS/MS.
As an example of the use of 4-APEBA derivatization in
the analysis of known aldehydes, urine samples of five
healthy volunteers were spiked with 20 nM (final concen-
tration) of hexanal, heptanal, octanal, nonanal, and decanal
prior to derivatization with 4-APEBA. The urine samples
Compounds tR Formula (M+) Score Mass Calc mass Abs diff (ppm)
Pentanal 11.14 C23H34BrN2O
+ 100 433.1860 433.18545 1.27
Hexanal 11.76 C24H36BrN2O
+ 100 447.20222 447.2011 2.50
Heptanal 12.42 C25H38BrN2O
+ 100 461.21465 461.21675 4.55
Octanal 13.10 C26H40BrN2O
+ 100 475.23164 475.2324 1.59
Nonanal 13.79 C27H42BrN2O
+ 100 489.2489 489.24805 1.74
Decanal 14.46 C28H44BrN2O
+ 100 503.26547 503.2637 3.51
Table 1 Chemical formulas
generated from extracted HR
mass measurements
Fig. 6 Analysis of aldehyde biomarkers in plasma. a Comparison of
extracted-ion chromatogram of m/z 477 for control (red) and AAPH-
treated (blue) plasma, b MS/MS spectrum of the elevated peak at
17 min. The following gradient was used: 100% mobile phase A (95%
H2O + 5% MeOH + 0.1% formic acid) was maintained for 5 min and
then solvent B (5% H2O + 95% MeOH + 0.1% formic acid) was
increased from 5% to 90% in 25 min (long gradient) with a 5-min
hold at 90% B. After this, the column was reconditioned for 10 min at
100% mobile phase A
Targeted LC–MS derivatization for aldehydes and carboxylic acids with 4-APEBA 673were analyzed using full-spectrum LC–MS. The five
combined extracted chromatograms (XIC) of pentanal,
hexanal, heptanal, octanal, nonanal, and decanal derivatives
are shown in Fig. 5. The peaks are labeled with the observed
peak areas (not corrected using the urinary creatinine value).
Although pentanal was not in the spike, it was detected in
two out of the five urine samples. Hexanal was observed
with an elevated peak area in one of the samples as well,
whereas heptanal, octanal, nonanal, and decanal showed
quite similar peak areas between the five samples. This
relatively simple experiment clearly demonstrates that
sample-to-sample variation can be detected.
Based on the accurate m/z values from the Q-TOF mass
spectrometer, the identity of the six derivatives was
confirmed with a mass accuracy within 5 ppm using
internal calibration, as demonstrated in Table 1.
Screeningandconfirmationforunknown4-APEBAderivatives
In order to demonstrate the potential of the 4-APEBA
derivatization in the nontargeted screening of aldehyde
biomarkers of LPO, we subjected human plasma to a
radical inducer (AAPH) to force oxidative conditions.
Human plasma prior to and after the AAPH treatment were
derivatized with 4-APEBA/NaBH3CN. Subsequently, LC–
MS and LC–MS/MS analysis was performed, and the data
were collected.
By comparison of the MS data for the control and the
AAPH-treated plasma, various new or elevated peaks
appeared (data not shown). MS/MS experiments were
performed to collect fragmentation data. Data for one of
the elevated peaks are shown in Fig. 6. The extracted-ion
chromatogram of m/z 477 shows two peaks, the first of
which is about twice as high in the treated plasma
compared to the control (Fig. 6a). Mass spectra of the two
peaks show a doublet with m/z 477 and 479 (ratio 100:98)
for the first peak and a doublet with m/z 475 and 477 (ratio
100:98) for the second peak (data not shown). This
indicates that both peaks (most likely) are 4-APEBA
derivatives. In the MS/MS spectrum, all the reactant-
specific fragments with m/z 183, 58, 72, and 104 were
present for both peaks. The MS/MS of the first elevated
peak is shown in Fig. 6b. Based on the accurate mass data,
chemical formulas were determined for both compounds in
Fig. 6a (see Electronic Supplementary Material Table S1
for the generated formulas with the two samples). The
formula of the second peak is consistent with an octanal
derivative. The formula of the first peak indicates the
presence of a C6 chain which, judging from the C/O ratio,
is highly oxidized, e.g., a C6 peroxide. The AAPH radical
inducer is known to generate peroxides [20]. This unknown
compound is also present in the control plasma. Further
identification of this unknown product was not attempted;
the MS/MS spectrum does not provide clear information for
further elucidation. The radical inducer neither increased
nor decreased the abundance of the octanal in the plasma,
which is somewhat in contrast to our earlier findings [28].
Nevertheless, this example shows how 4-APEBA derivati-
zation can be used to screen biological samples for both
known and unknown aldehydes and to detect elevated
levels of known or unknown aldehydes. Further research in
this direction is currently performed and results will be
reported in due course.
Conclusion
In the present publication, we demonstrate the design and
synthesis of the novel derivatization agent 4-APEBA.
Based on our first-generation reagent 4-APC, the design
of 4-APEBA addressed four stringent issues in biomarker
analysis. This led to the incorporation of a bromophenethyl
unit. The reagent can be used on either aldehydes (using
NaBH3CN as co-reagent) or carboxylic acids (using EDC
as co-reagent). The new features of 4-APEBA are perfectly
suited for screening and quantification purposes. The
incorporated bromine provides a clearly detectable doublet
in the mass spectra which significantly enhances peak
recognition. Compared to the first-generation reagent 4-
APC, 4-APEBA displays similar fragmentation patterns of
the adducts. However, it provides a clear surplus value
through the fixed neutral loss as well as one fixed charged
(monobromo) fragment (with m/z 183) for all derivatives.
This enables efficient screening for unknown biomarkers of
LPO. Using 4-APEBA in conjunction with MS/MS and
high-resolution MS (Q-TOF), we were able to detect
potential highly oxidized aldehyde species in human
plasma treated with AAPH. Future work from our labs will
elaborate further on the design platform for derivatization
reagents with the ultimate goal to identify these biomarkers.
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